Search

Your search keyword '"Torrebadell, Montserrat"' showing total 15 results
Start Over Author "Torrebadell, Montserrat" Publication Year Range Last 3 years
15 results on '"Torrebadell, Montserrat"'

1. MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment

Author

Garcia-Gerique, Laura, García, Marta, Garrido-Garcia, Alícia, Gómez-González, Soledad, Torrebadell, Montserrat, Prada, Estela, Pascual-Pasto, Guillem, Muñoz, Oscar, Perez-Jaume, Sara, Lemos, Isadora, Salvador, Noelia, Vila-Ubach, Monica, Doncel-Requena, Ana, Suñol, Mariona, Carcaboso, Angel M., Mora, Jaume, and Lavarino, Cinzia

Published
2022
Full Text
View/download PDF

2. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Author

Instituto de Biomedicina de Sevilla (IBIS), Universidad de Sevilla. Departamento de Medicina, Molinos-Quintana, Águeda, Alonso-Saladrigues, Anna, Herrero, Blanca, Caballero Velázquez, Teresa, Galán-Gómez, Víctor, Panesso, Melissa, Torrebadell, Montserrat, Delgado-Serrano, Javier, Pérez de Soto, Concepción, Pérez Simón, José Antonio, Instituto de Biomedicina de Sevilla (IBIS), Universidad de Sevilla. Departamento de Medicina, Molinos-Quintana, Águeda, Alonso-Saladrigues, Anna, Herrero, Blanca, Caballero Velázquez, Teresa, Galán-Gómez, Víctor, Panesso, Melissa, Torrebadell, Montserrat, Delgado-Serrano, Javier, Pérez de Soto, Concepción, and Pérez Simón, José Antonio

Abstract

Introduction: Loss of B-cell aplasia (BCA) is a well-known marker of functional loss of CD19 CAR-T. Most relapses and loss of BCA occur in the first months after CD19 CAR-T infusion. In addition, high tumor burden (HTB) has shown to have a strong impact on relapse, especially in CD19-negative. However, little is known about the impact of late loss of BCA or the relationship between BCA and preinfusion tumor burden in patients infused with tisagenlecleucel for relapsed/ refractory B-cell acute lymphoblastic leukemia. Therefore, the optimal management of patients with loss of BCA is yet to be defined. Methods: We conducted a Spanish, multicentre, retrospective study in patients infused with tisagenlecleucel after marketing authorization. A total of 73 consecutively treated patients were evaluated. Results: Prior to infusion, 39 patients had HTB (≥ 5% bone marrow blasts) whereas 34 had a low tumor burden (LTB) (<5% blasts). Complete remission was achieved in 90.4% of patients, of whom 59% relapsed. HTB was associated with inferior outcomes, with a 12-month EFS of 19.3% compared to 67.2% in patients with LTB (p<0.001) with a median follow-up of 13.5 months (95% CI 12.4 – 16.2). In the HTB subgroup relapses were mainly CD19-negative (72%) whereas in the LTB subgroup they were mainly CD19-positive (71%) (p=0.017). In the LTB group, all CD19-positive relapses were preceded by loss of BCA whereas only 57% (4/7) of HTB patients experienced CD19-positive relapse. We found a positive correlation between loss of BCA and CD19-positive relapse (Rsquared: 74) which persisted beyond six months post-infusion. We also explored B-cell recovery over time using two different definitions of loss of BCA and found a few discrepancies. Interestingly, transient immature B-cell recovery followed by BCA was observed in two pediatric patients. In conclusion, HTB has an unfavorable impact on EFS and allo-SCT might be considered in all patients with HTB, regardless of BCA. In patients with LTB, l

Published
2024

3. Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Author

Molinos-Quintana, Águeda, primary, Alonso-Saladrigues, Anna, additional, Herrero, Blanca, additional, Caballero-Velázquez, Teresa, additional, Galán-Gómez, Víctor, additional, Panesso, Melissa, additional, Torrebadell, Montserrat, additional, Delgado-Serrano, Javier, additional, Pérez de Soto, Concepción, additional, Faura, Anna, additional, González-Martínez, Berta, additional, Castillo-Robleda, Ana, additional, Diaz-de-Heredia, Cristina, additional, Pérez-Martínez, Antonio, additional, Pérez-Hurtado, José María, additional, Rives, Susana, additional, and Pérez-Simón, José Antonio, additional

Published
2024
Full Text
View/download PDF

4. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Author

Molinos-Quintana, Águeda, primary, Alonso-Saladrigues, Anna, additional, Herrero, Blanca, additional, Caballero-Velázquez, Teresa, additional, Galán-Gómez, Víctor, additional, Panesso, Melissa, additional, Torrebadell, Montserrat, additional, Delgado-Serrano, Javier, additional, Pérez de Soto, Concepción, additional, Faura, Anna, additional, González-Martínez, Berta, additional, Castillo-Robleda, Ana, additional, Diaz-de-Heredia, Cristina, additional, Pérez-Martínez, Antonio, additional, Pérez-Hurtado, José María, additional, Rives, Susana, additional, and Pérez-Simón, José Antonio, additional

Published
2024
Full Text
View/download PDF

5. P348: GENOMIC CHARACTERIZATION OF RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PEDIATRIC PATIENTS UNDERGOING CAR-T TREATMENT IN A SINGLE CENTER

Author

Esperanza Cebollada, Elena, primary, Vicente Garcés, Clara, additional, Alsonso, Anna, additional, Cuatrecasas Capdevila, Esther, additional, Andreu, Sandra, additional, Crespo Carrasco, Alba, additional, Richarte, Mercè, additional, Montesdeoca, Sara, additional, Torrebadell, Montserrat, additional, Camos Guijosa, Mireia, additional, Rives, Susana, additional, and Vega García, Nerea, additional

Published
2023
Full Text
View/download PDF

6. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Author

Molinos-Quintana, A., Alonso-Saladrigues, Anna, Herrero, Blanca, Caballero-Velázquez, Teresa, Galán-Gómez, Víctor, Panesso, Melissa, Torrebadell, Montserrat, Delgado-Serrano, Javier, Pérez de Soto, Concepción, Faura, Anna, González-Martínez, Berta, Castillo-Robleda, Ana, Díaz de Heredia, Cristina, Pérez-Martínez, Antonio, Pérez-Hurtado, José M., Rives, Susana, Pérez-Simón, José A., Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC), Molinos-Quintana, A., Alonso-Saladrigues, Anna, Herrero, Blanca, Caballero-Velázquez, Teresa, Galán-Gómez, Víctor, Panesso, Melissa, Torrebadell, Montserrat, Delgado-Serrano, Javier, Pérez de Soto, Concepción, Faura, Anna, González-Martínez, Berta, Castillo-Robleda, Ana, Díaz de Heredia, Cristina, Pérez-Martínez, Antonio, Pérez-Hurtado, José M., Rives, Susana, Pérez-Simón, José A., and Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)

Abstract

Introduction: Loss of B-cell aplasia (BCA) is a well-known marker of functional loss of CD19 CAR-T. Most relapses and loss of BCA occur in the first months after CD19 CAR-T infusion. In addition, high tumor burden (HTB) has shown to have a strong impact on relapse, especially in CD19-negative. However, little is known about the impact of late loss of BCA or the relationship between BCA and pre-infusion tumor burden in patients infused with tisagenlecleucel for relapsed/refractory B-cell acute lymphoblastic leukemia. Therefore, the optimal management of patients with loss of BCA is yet to be defined. Methods: We conducted a Spanish, multicentre, retrospective study in patients infused with tisagenlecleucel after marketing authorization. A total of 73 consecutively treated patients were evaluated. Results: Prior to infusion, 39 patients had HTB (≥ 5% bone marrow blasts) whereas 34 had a low tumor burden (LTB) (<5% blasts). Complete remission was achieved in 90.4% of patients, of whom 59% relapsed. HTB was associated with inferior outcomes, with a 12-month EFS of 19.3% compared to 67.2% in patients with LTB (p<0.001) with a median follow-up of 13.5 months (95% CI 12.4 – 16.2). In the HTB subgroup relapses were mainly CD19-negative (72%) whereas in the LTB subgroup they were mainly CD19-positive (71%) (p=0.017). In the LTB group, all CD19-positive relapses were preceded by loss of BCA whereas only 57% (4/7) of HTB patients experienced CD19-positive relapse. We found a positive correlation between loss of BCA and CD19-positive relapse (R-squared: 74) which persisted beyond six months post-infusion. We also explored B-cell recovery over time using two different definitions of loss of BCA and found a few discrepancies. Interestingly, transient immature B-cell recovery followed by BCA was observed in two pediatric patients. In conclusion, HTB has an unfavorable impact on EFS and allo-SCT might be considered in all patients with HTB, regardless of BCA. In patients with LTB

Published
2023

8. A miRNA signature related to stemness identifies high‐risk patients in paediatric acute myeloid leukaemia

Author

Esperanza‐Cebollada, Elena, primary, Gómez‐González, Soledad, additional, Perez‐Jaume, Sara, additional, Vega‐García, Nerea, additional, Vicente‐Garcés, Clara, additional, Richarte‐Franqués, Mercè, additional, Rives, Susana, additional, Català, Albert, additional, Torrebadell, Montserrat, additional, and Camós, Mireia, additional

Published
2023
Full Text
View/download PDF

9. Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia

Author

Vicente-Garcés, Clara, primary, Esperanza-Cebollada, Elena, additional, Montesdeoca, Sara, additional, Torrebadell, Montserrat, additional, Rives, Susana, additional, Dapena, José Luis, additional, Català, Albert, additional, Conde, Nuria, additional, Camós, Mireia, additional, and Vega-García, Nerea, additional

Published
2022
Full Text
View/download PDF

10. Results of ARI ‐0001 CART19 cell therapy in patients with relapsed/refractory CD19 ‐positive acute lymphoblastic leukemia with isolated extramedullary disease

Author

Ortiz‐Maldonado, Valentín, primary, Alonso‐Saladrigues, Anna, additional, Español‐Rego, Marta, additional, Martínez‐Cibrián, Nuria, additional, Faura, Anna, additional, Magnano, Laura, additional, Català, Albert, additional, Benítez‐Ribas, Daniel, additional, Giné, Eva, additional, Díaz‐Beyá, Marina, additional, Correa, Juan Gonzalo, additional, Rovira, Montserrat, additional, Montoro‐Lorite, Mercedes, additional, Martínez‐Roca, Alexandra, additional, Rodríguez‐Lobato, Luis Gerardo, additional, Cabezón, Raquel, additional, Cid, Joan, additional, Lozano, Miquel, additional, Garcia‐Rey, Enric, additional, Conde, Nuria, additional, Pedrals, Georgina, additional, Rozman, María, additional, Torrebadell, Montserrat, additional, Setoain, Xavier, additional, Rodríguez, Sonia, additional, Esteve, Jordi, additional, Pascal, Mariona, additional, Urbano‐Ispizua, Álvaro, additional, Juan, Manel, additional, Delgado, Julio, additional, and Rives, Susana, additional

Published
2022
Full Text
View/download PDF

11. A comprehensive single-cell expression atlas of human AML leukemia-initiating cells unravels the contribution of HIF pathway and its therapeutic potential

Author

Velasco-Hernandez, Talia, primary, Trincado, Juan L., additional, Vinyoles, Meritxell, additional, Closa, Adria, additional, Gutiérrez-Agüera, Francisco, additional, Molina, Oscar, additional, Rodríguez-Cortez, Virginia C, additional, Petazzi, Paolo, additional, Beneyto-Calabuig, Sergi, additional, Velten, Lars, additional, Romecin, Paola, additional, Casquero, Raquel, additional, Abollo-Jiménez, Fernando, additional, Díaz de la Guardia, Rafael, additional, Lorden, Patricia, additional, Bataller, Alex, additional, Lapillonne, Helene, additional, Stam, Ronald W, additional, Vives, Susana, additional, Torrebadell, Montserrat, additional, Fuster, Jose Luis, additional, Bueno, Clara, additional, Eyras, Eduardo, additional, Heyn, Holger, additional, and Menéndez, Pablo, additional

Published
2022
Full Text
View/download PDF

12. Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

Author

Ortiz-Maldonado, Valentín, primary, Rives, Susana, additional, Español-Rego, Marta, additional, Alonso-Saladrigues, Anna, additional, Montoro, Mercedes, additional, Magnano, Laura, additional, Giné, Eva, additional, Pascal, Mariona, additional, Díaz-Beyá, Marina, additional, Castella, Maria, additional, Català, Albert, additional, Faura, Anna, additional, Rodríguez-Lobato, Luis Gerardo, additional, Oliver-Caldes, Aina, additional, Martínez-Roca, Alexandra, additional, Rovira, Montserrat, additional, González-Navarro, E Azucena, additional, Ortega, Juan Ramón, additional, Cid, Joan, additional, Lozano, Miquel, additional, Garcia-Rey, Enric, additional, Fernández, Sara, additional, Castro, Pedro, additional, Jordan, Iolanda, additional, Villamor, Neus, additional, Aymerich, Marta, additional, Torrebadell, Montserrat, additional, Deyà, Àngela, additional, Fernández de Larrea, Carlos, additional, Benitez-Ribas, Daniel, additional, Trias, Esteve, additional, Varea, Sara, additional, Calvo, Gonzalo, additional, Esteve, Jordi, additional, Urbano-Ispizua, Alvaro, additional, Juan, Manel, additional, and Delgado, Julio, additional

Published
2021
Full Text
View/download PDF

13. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.

Author

Velasco-Hernandez T, Trincado JL, Vinyoles M, Closa A, Martínez-Moreno A, Gutiérrez-Agüera F, Molina O, Rodríguez-Cortez VC, Ximeno-Parpal P, Fernández-Fuentes N, Petazzi P, Beneyto-Calabuig S, Velten L, Romecin P, Casquero R, Abollo-Jiménez F, de la Guardia RD, Lorden P, Bataller A, Lapillonne H, Stam RW, Vives S, Torrebadell M, Fuster JL, Bueno C, Sarry JE, Eyras E, Heyn H, and Menéndez P

Abstract

Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIF high and HIF low specific AML subgroups (inv(16)/ t (8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs., Competing Interests: Pablo Menéndez is the founder of the spin‐off OneChain Immunotherapeutics, which has no connection with the present research. The other authors declare no conflict of interest., (© 2024 The Authors. HemaSphere published by John Wiley & Sons Ltd. on behalf of European Hematology Association.)

Published
2024
Full Text
View/download PDF

14. An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.

Author

Maurer-Granofszky M, Schumich A, Buldini B, Gaipa G, Kappelmayer J, Mejstrikova E, Karawajew L, Rossi J, Suzan AÇ, Agriello E, Anastasiou-Grenzelia T, Barcala V, Barna G, Batinić D, Bourquin JP, Brüggemann M, Bukowska-Strakova K, Burnusuzov H, Carelli D, Deniz G, Dubravčić K, Feuerstein T, Gaillard MI, Galeano A, Giordano H, Gonzalez A, Groeneveld-Krentz S, Hevessy Z, Hrusak O, Iarossi MB, Jáksó P, Kloboves Prevodnik V, Kohlscheen S, Kreminska E, Maglia O, Malusardi C, Marinov N, Martin BM, Möller C, Nikulshin S, Palazzi J, Paterakis G, Popov A, Ratei R, Rodríguez C, Sajaroff EO, Sala S, Samardzija G, Sartor M, Scarparo P, Sędek Ł, Slavkovic B, Solari L, Svec P, Szczepanski T, Taparkou A, Torrebadell M, Tzanoudaki M, Varotto E, Vernitsky H, Attarbaschi A, Schrappe M, Conter V, Biondi A, Felice M, Campbell M, Kiss C, Basso G, Dworzak MN, and On Behalf Of I-Bfm-Flow-Network

Abstract

Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning maturation program, (ii) obligatory participation in external QA programs (spiked sample send around, United Kingdom National External Quality Assessment Service (UK NEQAS)), (iii) regular participation in list-mode-data (LMD) file ring trials (FCM data file send arounds), and (iv) surveys of independent data derived from trial results. We demonstrate that the training of laboratories using experienced twinning partners, along with continuous educational feedback significantly improves the performance of laboratories in detecting and quantifying MRD in pediatric ALL patients. Overall, our extensive education and quality control program improved inter-laboratory concordance rates of FCM-MRD assessments and ultimately led to a very high conformity of risk estimates in independent patient cohorts.

Published
2021
Full Text
View/download PDF

15. Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.

Author

Ortiz-Maldonado V, Rives S, Español-Rego M, Alonso-Saladrigues A, Montoro M, Magnano L, Giné E, Pascal M, Díaz-Beyá M, Castella M, Català A, Faura A, Rodríguez-Lobato LG, Oliver-Caldes A, Martínez-Roca A, Rovira M, González-Navarro EA, Ortega JR, Cid J, Lozano M, Garcia-Rey E, Fernández S, Castro P, Jordan I, Villamor N, Aymerich M, Torrebadell M, Deyà À, Fernández de Larrea C, Benitez-Ribas D, Trias E, Varea S, Calvo G, Esteve J, Urbano-Ispizua A, Juan M, and Delgado J

Subjects
Adolescent, Adult, Aged, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local immunology, Neoplasm Recurrence, Local pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Prognosis, Survival Rate, Young Adult, Antigens, CD19 immunology, Cell- and Tissue-Based Therapy methods, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Receptors, Antigen, T-Cell immunology, Salvage Therapy
Abstract

Competing Interests: Competing interests: VO-M: Consultant or advisory role (Kite Gilead, Celgene, Novartis), travel grants (Kite Gilead, Celgene, Novartis, Roche, Takeda, Janssen), honoraria (Kite Gilead). SR: Consultant or advisory role (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead), travel grants (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead), honoraria (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead). AA-S: Consultant or advisory role (Novartis), travel grants (Novartis), honoraria (Novartis). EG: Consultant or advisory role (Kite Gilead, Janssen, Genmab), research funding (Kite Gilead, Janssen, Roche). MD-B: Consultant or advisory role (Celgene, Novartis, Jazz, Astellas). AC: Consultant or advisory role (Novartis, Celgene), travel grants (Novartis, Celgene), honoraria (Novartis, Celgene). AF: Consultant or advisory role (Novartis), travel grants (Novartis), honoraria (Novartis). LGR-L: Travel grants (Kite Gilead, Amgen, Janssen). ML: Honoraria (Grifols, Fresenius Kabi), research funding (Terumo BCT, Maco-Pharma). AM-R: Consultant or advisory role (Bristol Myers Squibb, Abbvie), travel grants (Kite Gilead, Roche, Takeda, Janssen, Abbvie), honoraria (Abbvie). EG-R: Honoraria (Novartis). PC: Consultant or advisory role (Kite Gilead, Celgene, Janssen), travel grants (Kite Gilead, MSD, Janssen). MT: Consultant or advisory role (Novartis). CFDL: Consultant or advisory role (Janssen, Celgene/Bristol-Myers, GSK), honoraria (Janssen, Celgene/Bristol-Myers, Amgen, GSK), research funding (Janssen, Celgene/Bristol-Myers, Amgen, Takeda). GC: Consultant or advisory role (Celgene, Novartis). JE: Consultant or advisory role (Abbvie, Novartis, Celgene, Astellas, Jazz, Daiichi Dankyo, Roche, Amgen, Pfizer), travel grants (Celgene, Roche, Astellas, Daiichi Dankyo), research funding (Novartis, Celgene). AU-I: Consultant or advisory role (Kite Gilead, Celgene/Bristol-Myers, Miltenyi), travel grants (Kite Gilead, Celgene/Bristol-Myers). MJ: Consultant or advisory role (Kite Gilead, Grifols), honoraria (Kite Gilead, Grifols).

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results